Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miranda D Grounds

Showing results (51-60 of 121) with videos related to

Pageof 13
Sort By:
Cell and Tissue Research|April 23, 2005
Silencing TNFalpha activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in miceMiranda D Grounds, Marilyn Davies, Jo Torrisi, et al.
Biomedical Optics Express|April 25, 2014
Optical coherence tomography can assess skeletal muscle tissue from mouse models of muscular dystrophy by parametric imaging of the attenuation coefficientBlake R Klyen, Loretta Scolaro, Tea Shavlakadze, et al.
Antioxidants (Basel, Switzerland)|August 27, 2021
A Blood Biomarker for Duchenne Muscular Dystrophy Shows That Oxidation State of Albumin Correlates with Protein Oxidation and Damage in Mdx MuscleBasma A Al-Mshhdani, Miranda D Grounds, Peter G Arthur, et al.
Cell Motility and the Cytoskeleton|October 20, 2007
Myoseverin disrupts sarcomeric organization in myocytes: an effect independent of microtubule assembly inhibitionDominic C H Ng, Bijanka L Gebski, Miranda D Grounds, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 29, 2004
Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx miceThea Shavlakadze, Jason White, Joseph F Y Hoh, et al.
Neuromuscular Disorders : NMD|December 31, 2011
N-Acetylcysteine treatment of dystrophic mdx mice results in protein thiol modifications and inhibition of exercise induced myofibre necrosisJessica R Terrill, Hannah G Radley-Crabb, Miranda D Grounds, et al.
Clinical and Experimental Pharmacology & Physiology|January 25, 2008
Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscleMiranda D Grounds, Hannah G Radley, Bijanka L Gebski, et al.
Neurobiology of Disease|May 24, 2008
Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophyMiranda D Grounds, Hannah G Radley, Gordon S Lynch, et al.
Plos One|May 22, 2023
Correction: Dysferlin-deficiency has greater impact on function of slow muscles, compared with fast, in aged BLAJ miceErin M Lloyd, Hongyang Xu, Robyn M Murphy, et al.
Plos One|April 11, 2019
Dysferlin-deficiency has greater impact on function of slow muscles, compared with fast, in aged BLAJ miceErin M Lloyd, Hongyang Xu, Robyn M Murphy, et al.
Pageof 13

Showing results (51-60 of 121) with videos related to

Sort By:
Pageof 13
Cell and Tissue Research|April 23, 2005
Silencing TNFalpha activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in miceMiranda D Grounds, Marilyn Davies, Jo Torrisi, et al.
Biomedical Optics Express|April 25, 2014
Optical coherence tomography can assess skeletal muscle tissue from mouse models of muscular dystrophy by parametric imaging of the attenuation coefficientBlake R Klyen, Loretta Scolaro, Tea Shavlakadze, et al.
Antioxidants (Basel, Switzerland)|August 27, 2021
A Blood Biomarker for Duchenne Muscular Dystrophy Shows That Oxidation State of Albumin Correlates with Protein Oxidation and Damage in Mdx MuscleBasma A Al-Mshhdani, Miranda D Grounds, Peter G Arthur, et al.
Cell Motility and the Cytoskeleton|October 20, 2007
Myoseverin disrupts sarcomeric organization in myocytes: an effect independent of microtubule assembly inhibitionDominic C H Ng, Bijanka L Gebski, Miranda D Grounds, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 29, 2004
Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx miceThea Shavlakadze, Jason White, Joseph F Y Hoh, et al.
Neuromuscular Disorders : NMD|December 31, 2011
N-Acetylcysteine treatment of dystrophic mdx mice results in protein thiol modifications and inhibition of exercise induced myofibre necrosisJessica R Terrill, Hannah G Radley-Crabb, Miranda D Grounds, et al.
Clinical and Experimental Pharmacology & Physiology|January 25, 2008
Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscleMiranda D Grounds, Hannah G Radley, Bijanka L Gebski, et al.
Neurobiology of Disease|May 24, 2008
Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophyMiranda D Grounds, Hannah G Radley, Gordon S Lynch, et al.
Plos One|May 22, 2023
Correction: Dysferlin-deficiency has greater impact on function of slow muscles, compared with fast, in aged BLAJ miceErin M Lloyd, Hongyang Xu, Robyn M Murphy, et al.
Plos One|April 11, 2019
Dysferlin-deficiency has greater impact on function of slow muscles, compared with fast, in aged BLAJ miceErin M Lloyd, Hongyang Xu, Robyn M Murphy, et al.
Pageof 13